Galzin (zinc acetate)Company: Teva Pharmaceutical
Approval Status: Approved January 1997
Treatment for: Wilson’s disease
Areas: Neurology & Nervous System; Pharmacology
Galzin has been approved for the treatment of Wilson's disease. Wilson’s disease is a potentially fatal inherited abnormality, occurring in one of 30,000 people, that causes excess copper to accumulate in the body, affecting the liver and the brain. Patients become ill as teenagers or as young adults with liver disease, often with neurologic symptoms. Galzin works by blocking absorption of copper from the intestine.
Galzin Drug Information
The Galzin drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.